I was wondering about his approach to the SP after the CR. Do you think it crossed his mind that attempting to have the company dragged through the mud of an investigation and getting the directors charged might possibly have an even greater negative impact on the company - and all of our investments with it - than the temporary setback in SP associated with the slightly odorous yet successful raising of the funds that ensues BOT can continue trials without the onus of cash shortage hanging over our heads ?
“Cutting off your nose to spite your face “seems appropriate.
Ann: FDA Clears Development Path for BTX 1204, page-15
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.010(2.86%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 33.5¢ | $588.0K | 1.730M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2571 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 138117 | 5 |
View Market Depth
| Last trade - 16.10pm 03/12/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
